Randomized trial · people

SS-31: less kidney hypoxia after renal artery stenting in pilot

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a small human pilot trial, SS-31 given during kidney artery stenting was linked to less kidney oxygen loss right after the procedure and better kidney blood flow and filtering 3 months later.

Kind
Randomized trial
Studied in
People
Published
2017
Journal
Circ Cardiovasc Interv

What they tested

The team tested whether giving elamipretide (SS-31) around a kidney artery stenting procedure would improve kidney function, oxygen levels and blood flow in people with a narrowed kidney artery.

How the study was done

A randomized, placebo-controlled phase 2a pilot trial in patients with severe narrowing of a kidney artery from plaque buildup who were scheduled for angioplasty and stenting (PTRA). Patients got an intravenous infusion of elamipretide at 0.05 mg/kg per hour (6 patients) or placebo, a dummy infusion (8 patients), before and during the procedure, with kidney scans before and 3 months after.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

One day after stenting, the share of the kidney with low oxygen (fractional hypoxia) went up 47% in the placebo group but went down 6% in the elamipretide group, and both returned to baseline by 3 months. Blood flow to the narrowed kidney rose from 202±29 to 262±115 mL/min at 3 months (P=0.04), and this rise was seen only in the elamipretide group. Over 3 months, systolic blood pressure fell and estimated glomerular filtration rate (eGFR, a measure of how well the kidneys filter) rose more with elamipretide (P=0.003) than with placebo (P=0.11).

What it doesn’t show

This was a very small pilot trial with 6 and 8 patients per group, so the results are early and need confirming in larger trials. Follow-up lasted only 3 months, and the drug was tested only around a single stenting procedure.

The paper

Saad et al. Phase 2a Clinical Trial of Mitochondrial Protection (Elamipretide) During Stent Revascularization in Patients With Atherosclerotic Renal Artery Stenosis. Circ Cardiovasc Interv. 2017.

The compound

More studies on SS-31

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking SS-31? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo